Monte Rosa Therapeutics, Inc. (GLUE)

Market Cap	156.25M
Revenue (ttm)	n/a
Net Income (ttm)	-132.88M
Shares Out	50.08M
EPS (ttm)	-2.69
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	129,216
Open	3.07
Previous Close	3.08
Day's Range	2.98 - 3.21
52-Week Range	2.44 - 9.65
Beta	1.13
Analysts	Buy
Price Target	13.67 (+348.2%)
Earnings Date	Nov 9, 2023

About GLUE

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops an orally bioavailable molecular glue degrader for GSPT1, a a translation termination factor for the treatment of Myc-driven cancers. It also develops CDK2 to treat ovarian, uterine, and breast cancers; NEK7 for the treatment of inflammatory diseases, such as gout and Crohn's disease, n...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 24, 2021
• Employees: 133
• Stock Exchange: NASDAQ
• Ticker Symbol: GLUE

Analyst Forecast

According to 3 analysts, the average rating for GLUE stock is "Buy." The 12-month stock price forecast is $13.67, which is an increase of 348.20% from the latest price.

Price Target

$13.67

(348.20% upside)

Analyst Consensus: Buy